title: Clinical application of bilateral high temporal and spatial resolution dynamic contrast-enhanced magnetic resonance imaging of the breast at 7 T.
abstract: OBJECTIVE
  The objective of our study was to evaluate the clinical application of bilateral high spatial and temporal resolution dynamic contrast-enhanced magnetic resonance imaging (HR DCE-MRI) of the breast at 7 T.
  
  
  METHODS
  Following institutional review board approval 23 patients with a breast lesion (BIRADS 0, 4-5) were included in our prospective study. All patients underwent bilateral HR DCE-MRI of the breast at 7 T (spatial resolution of 0.7 mm(3) voxel size, temporal resolution of 14 s). Two experienced readers (r1, r2) and one less experienced reader (r3) independently assessed lesions according to BI-RADS®. Image quality, lesion conspicuity and artefacts were graded from 1 to 5. Sensitivity, specificity and diagnostic accuracy were assessed using histopathology as the standard of reference.
  
  
  RESULTS
  HR DCE-MRI at 7 T revealed 29 lesions in 23 patients (sensitivity 100 % (19/19); specificity of 90 % (9/10)) resulting in a diagnostic accuracy of 96.6 % (28/29) with an AUC of 0.95. Overall image quality was excellent in the majority of cases (27/29) and examinations were not hampered by artefacts. There was excellent inter-reader agreement for diagnosis and image quality parameters (κ = 0.89-1).
  
  
  CONCLUSIONS
  Bilateral HR DCE-MRI of the breast at 7 T is feasible with excellent image quality in clinical practice and allows accurate breast cancer diagnosis.
  
  
  CONCLUSIONS
  • Dynamic contrast-enhanced 7-T MRI is being developed in several centres. • Bilateral high resolution DCE-MRI of the breast at 7 T is clinically applicable. • 7-T HR DCE-MRI of the breast provides excellent image quality. • 7-T HR DCE-MRI should detect breast cancer with high diagnostic accuracy.
authors.affiliation: Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Pinker
authors.forename: W
authors.initials: W
authors.lastname: Bogner
authors.forename: P
authors.initials: P
authors.lastname: Baltzer
authors.forename: S
authors.initials: S
authors.lastname: Trattnig
authors.forename: S
authors.initials: S
authors.lastname: Gruber
authors.forename: O
authors.initials: O
authors.lastname: Abeyakoon
authors.forename: M
authors.initials: M
authors.lastname: Bernathova
authors.forename: O
authors.initials: O
authors.lastname: Zaric
authors.forename: P
authors.initials: P
authors.lastname: Dubsky
authors.forename: Z
authors.initials: Z
authors.lastname: Bago-Horvath
authors.forename: M
authors.initials: M
authors.lastname: Weber
authors.forename: D
authors.initials: D
authors.lastname: Leithner
authors.forename: T H
authors.initials: TH
authors.lastname: Helbich
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001940:Breast / Q000473:pathology*; D001943:Breast Neoplasms / Q000473:pathology*; D003287:Contrast Media; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine; D008875:Middle Aged; D009942:Organometallic Compounds; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D008536:Meglumine; C072417:gadoterate meglumine